Retatrutide RT30 30mg*10vials

Retatroptide RT30 30mg*10 vials is the flagship high-dose version in the entire retatroptide tri-target receptor agonist peptide series. As the most potent and highest-concentration GLP-1/GIP/GCGR tri-target metabolic research peptide currently available, RT30 utilizes comprehensively upgraded superaffinity molecular optimization technology, surpassing RT10, RT15, ​​and RT20 in receptor binding efficiency, bioactivity intensity, and metabolic regulatory amplitude. RT30 is specifically designed for top-tier preclinical mechanism studies, ultra-high dose gradient experiments, extreme metabolic model construction, and high-standard efficacy validation, making it the preferred raw material for cutting-edge metabolic pharmacology research.

Product Functions and Research Value

Retatroptide RT30 exhibits superior synergistic metabolic regulation through three pathways. The highly activated GLP-1 and GIP dual pathways effectively improve insulin sensitivity, correct glucose metabolism disorders, stabilize blood glucose homeostasis, and produce potent and long-lasting appetite suppression and satiety maintenance effects, thereby supporting in-depth research on glucose and lipid metabolism and insulin resistance in diabetes. The significantly enhanced GCGR pathway maximizes resting energy expenditure, significantly accelerates visceral fat breakdown and systemic lipid oxidation, effectively improves severe dyslipidemia, and promotes white adipose tissue remodeling. RT30 provides highly significant experimental phenotypes and high-precision, high-reliability raw data for challenging studies, including those on severe refractory obesity, long-term metabolic remodeling, metabolic liver injury, and extreme dose-response correlations.

Core Product Advantages

1. Flagship-Level Ultimate Activity: RT30 is the top-tier iteration in the Retatrutide series, featuring a comprehensively upgraded molecular structure and extremely high target affinity. Its comprehensive metabolic regulatory capabilities far surpass those of RT10, RT15, ​​and RT20, delivering more significant experimental differences and meeting the stringent standards of cutting-edge scientific research.

2. Ultra-High 30mg Single-Venue Concentration: The highest commercial specification in the RT series, with a concentration three times that of the traditional 10mg product and 50% higher than the 20mg version. It is perfectly suited for long-term large animal models, ultra-high dose gradient controlled trials, and large-scale repetitive sample experiments, minimizing errors caused by frequent dilution and reagent changes. 3. Extremely high stability and ultra-long-lasting effect: Advanced anti-degradation molecular modification technology resists in vitro and in vivo metabolic attenuation, maintaining extremely high bioactivity throughout long-term experimental periods and obtaining extremely stable and reproducible data.

4. Pharmaceutical-grade high purity: Utilizing aseptic vacuum freeze-drying technology, the peptide's activity is completely locked in. Each batch undergoes rigorous HPLC purity testing and comes with complete COA quality certification, featuring ultra-low impurity content and zero contamination risk.

5. Standardized bulk packaging: 10 vials per box, integrated packaging, ideal for long-term laboratory storage, core preclinical drug research, key university research projects, and large-volume wholesale purchases.

Retatrutide RT30 30mg*10 vials, a flagship high-dose, ultra-efficient triple receptor agonist peptide. An upgraded version targeting GLP-1/GIP/GCGR, suitable for extreme metabolic models, severe obesity, and top-tier preclinical laboratory research. Highest concentration, strongest activity, ultra-stable performance, with complete COA certification, available for wholesale.